121 related articles for article (PubMed ID: 19995558)
1. LMO3 interacts with p53 and inhibits its transcriptional activity.
Larsen S; Yokochi T; Isogai E; Nakamura Y; Ozaki T; Nakagawara A
Biochem Biophys Res Commun; 2010 Feb; 392(3):252-7. PubMed ID: 19995558
[TBL] [Abstract][Full Text] [Related]
2. LMO3 interacts with neuronal transcription factor, HEN2, and acts as an oncogene in neuroblastoma.
Aoyama M; Ozaki T; Inuzuka H; Tomotsune D; Hirato J; Okamoto Y; Tokita H; Ohira M; Nakagawara A
Cancer Res; 2005 Jun; 65(11):4587-97. PubMed ID: 15930276
[TBL] [Abstract][Full Text] [Related]
3. The BCL6 proto-oncogene suppresses p53 expression in germinal-centre B cells.
Phan RT; Dalla-Favera R
Nature; 2004 Dec; 432(7017):635-9. PubMed ID: 15577913
[TBL] [Abstract][Full Text] [Related]
4. Methods to study p53-repressed promoters.
Dumont P; Della Pietra A; Murphy ME
Methods Mol Biol; 2003; 234():111-20. PubMed ID: 12824528
[TBL] [Abstract][Full Text] [Related]
5. Tumor-specific adenoviral gene therapy: transcriptional repression of gene expression by utilizing p53-signal transduction pathways.
Kühnel F; Zender L; Wirth T; Schulte B; Trautwein C; Manns M; Kubicka S
Cancer Gene Ther; 2004 Jan; 11(1):28-40. PubMed ID: 14681724
[TBL] [Abstract][Full Text] [Related]
6. Negative regulation of bcl-2 expression by p53 in hematopoietic cells.
Wu Y; Mehew JW; Heckman CA; Arcinas M; Boxer LM
Oncogene; 2001 Jan; 20(2):240-51. PubMed ID: 11313951
[TBL] [Abstract][Full Text] [Related]
7. ETS1 and ETS2 in p53 regulation: spatial separation of ETS binding sites (EBS) modulate protein: DNA interaction.
Venanzoni MC; Robinson LR; Hodge DR; Kola I; Seth A
Oncogene; 1996 Mar; 12(6):1199-1204. PubMed ID: 8649821
[TBL] [Abstract][Full Text] [Related]
8. The highly related LIM factors, LMO1, LMO3 and LMO4, play different roles in the regulation of the pituitary glycoprotein hormone alpha-subunit (alpha GSU) gene.
Susa T; Ishikawa A; Cai LY; Kato T; Matsumoto K; Kitahara K; Kurokawa R; Ono T; Kato Y
Biosci Rep; 2009 Oct; 30(1):51-8. PubMed ID: 19228115
[TBL] [Abstract][Full Text] [Related]
9. ING1 represses transcription by direct DNA binding and through effects on p53.
Kataoka H; Bonnefin P; Vieyra D; Feng X; Hara Y; Miura Y; Joh T; Nakabayashi H; Vaziri H; Harris CC; Riabowol K
Cancer Res; 2003 Sep; 63(18):5785-92. PubMed ID: 14522900
[TBL] [Abstract][Full Text] [Related]
10. The neurogene BTG2TIS21/PC3 is transactivated by DeltaNp73alpha via p53 specifically in neuroblastoma cells.
Goldschneider D; Million K; Meiller A; Haddada H; Puisieux A; Bénard J; May E; Douc-Rasy S
J Cell Sci; 2005 Mar; 118(Pt 6):1245-53. PubMed ID: 15741235
[TBL] [Abstract][Full Text] [Related]
11. Localization of a mutant p53 response element on the tissue inhibitor of metalloproteinase-3 promoter: mutant p53 activities are distinct from wild-type.
Thomas S; Reisman D
Cancer Lett; 2006 Aug; 240(1):48-59. PubMed ID: 16236433
[TBL] [Abstract][Full Text] [Related]
12. p53 is a NF-Y- and p21-independent, Sp1-dependent repressor of cyclin B1 transcription.
Innocente SA; Lee JM
FEBS Lett; 2005 Feb; 579(5):1001-7. PubMed ID: 15710382
[TBL] [Abstract][Full Text] [Related]
13. Global transcriptional program of p53 target genes during the process of apoptosis and cell cycle progression.
Mirza A; Wu Q; Wang L; McClanahan T; Bishop WR; Gheyas F; Ding W; Hutchins B; Hockenberry T; Kirschmeier P; Greene JR; Liu S
Oncogene; 2003 Jun; 22(23):3645-54. PubMed ID: 12789273
[TBL] [Abstract][Full Text] [Related]
14. Positive and negative regulation of deltaN-p63 promoter activity by p53 and deltaN-p63-alpha contributes to differential regulation of p53 target genes.
Harmes DC; Bresnick E; Lubin EA; Watson JK; Heim KE; Curtin JC; Suskind AM; Lamb J; DiRenzo J
Oncogene; 2003 Oct; 22(48):7607-16. PubMed ID: 14576823
[TBL] [Abstract][Full Text] [Related]
15. The oncoprotein LMO3 interacts with calcium- and integrin-binding protein CIB.
Hui L; Ji C; Hui B; Lv T; Ha X; Yang J; Cai W
Brain Res; 2009 Apr; 1265():24-9. PubMed ID: 19236851
[TBL] [Abstract][Full Text] [Related]
16. Activated Notch1 interacts with p53 to inhibit its phosphorylation and transactivation.
Kim SB; Chae GW; Lee J; Park J; Tak H; Chung JH; Park TG; Ahn JK; Joe CO
Cell Death Differ; 2007 May; 14(5):982-91. PubMed ID: 17186020
[TBL] [Abstract][Full Text] [Related]
17. p53-mediated downregulation of H ferritin promoter transcriptional efficiency via NF-Y.
Faniello MC; Di Sanzo M; Quaresima B; Baudi F; Di Caro V; Cuda G; Morrone G; Del Sal G; Spinelli G; Venuta S; Costanzo F
Int J Biochem Cell Biol; 2008; 40(10):2110-9. PubMed ID: 18372207
[TBL] [Abstract][Full Text] [Related]
18. The cell-cycle regulator geminin inhibits Hox function through direct and polycomb-mediated interactions.
Luo L; Yang X; Takihara Y; Knoetgen H; Kessel M
Nature; 2004 Feb; 427(6976):749-53. PubMed ID: 14973489
[TBL] [Abstract][Full Text] [Related]
19. YY1 binding to a subset of p53 DNA-target sites regulates p53-dependent transcription.
Yakovleva T; Kolesnikova L; Vukojević V; Gileva I; Tan-No K; Austen M; Lüscher B; Ekström TJ; Terenius L; Bakalkin G
Biochem Biophys Res Commun; 2004 May; 318(2):615-24. PubMed ID: 15120643
[TBL] [Abstract][Full Text] [Related]
20. Role of Stat3 in regulating p53 expression and function.
Niu G; Wright KL; Ma Y; Wright GM; Huang M; Irby R; Briggs J; Karras J; Cress WD; Pardoll D; Jove R; Chen J; Yu H
Mol Cell Biol; 2005 Sep; 25(17):7432-40. PubMed ID: 16107692
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
